Details of the Drug

General Information of Drug (ID: DMPIM9L)

Drug Name
PMID28870136-Compound-48
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 180.16
Topological Polar Surface Area (xlogp) 0
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [1]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.86 mL/min/kg [2]
Elimination
18% of drug is excreted from urine in the unchanged form [1]
Half-life
The concentration or amount of drug in body reduced by one-half in 7.2 hours [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 48.12191 micromolar/kg/day [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.61% [2]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.51 L/kg [2]
Water Solubility
The ability of drug to dissolve in water is measured as 8.3 mg/mL [1]
Chemical Identifiers
Formula
C7H8N4O2
IUPAC Name
1,3-dimethyl-7H-purine-2,6-dione
Canonical SMILES
CN1C2=C(C(=O)N(C1=O)C)NC=N2
InChI
InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)
InChIKey
ZFXYFBGIUFBOJW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2153
ChEBI ID
CHEBI:28177
CAS Number
58-55-9
DrugBank ID
DB00277
TTD ID
D0DF2M
ACDINA ID
D00670

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ecto-5'-nucleotidase (CD73) TTK0O6Y 5NTD_HUMAN Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Ecto-5'-nucleotidase (CD73) DTT NT5E 9.56E-01 0.33 0.37
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from PMID28870136-Compound-48 (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Metreleptin mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [12]
Emapalumab DMZG5WL Moderate Altered metabolism of PMID28870136-Compound-48 due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [13]
Tacrine DM51FY6 Moderate Increased plasma concentrations of PMID28870136-Compound-48 and Tacrine due to competitive inhibition of the same metabolic pathway. Alzheimer disease [8A20] [14]
Siltuximab DMGEATB Moderate Altered metabolism of PMID28870136-Compound-48 due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [13]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of PMID28870136-Compound-48 caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [15]
Voriconazole DMAOL2S Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [16]
Zileuton DMVRIC2 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [17]
Obeticholic acid DM3Q1SM Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Obeticholic acid mediated inhibition of CYP450 enzyme. Autoimmune liver disease [DB96] [18]
Ofloxacin DM0VQN3 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Ofloxacin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [19]
Ciprofloxacin XR DM2NLS9 Major Decreased metabolism of PMID28870136-Compound-48 caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [20]
Clarithromycin DM4M1SG Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [21]
Norfloxacin DMIZ6W2 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Norfloxacin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [19]
Oxytetracycline DMOVH1M Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Oxytetracycline mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Troleandomycin DMUZNIG Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [21]
Minocycline DMVN5OH Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Minocycline mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Tetracycline DMZA017 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Tetracycline mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Estradiol DMUNTE3 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Estradiol. Breast cancer [2C60-2C6Y] [23]
Grepafloxacin DMGLX0T Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Grepafloxacin mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [24]
Demeclocycline DMZEPFJ Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Demeclocycline mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [22]
Secobarbital DM14RF5 Moderate Increased metabolism of PMID28870136-Compound-48 caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [15]
Drospirenone DM1A9W3 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Drospirenone. Contraceptive management [QA21] [23]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Levonorgestrel. Contraceptive management [QA21] [23]
Etonogestrel DMKA8J4 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Etonogestrel. Contraceptive management [QA21] [23]
Methohexital DM7YMIT Moderate Increased metabolism of PMID28870136-Compound-48 caused by Methohexital mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [15]
Thiopental DMGP8AX Moderate Increased metabolism of PMID28870136-Compound-48 caused by Thiopental mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [15]
Ropivacaine DMSPJG2 Minor Increased plasma concentrations of PMID28870136-Compound-48 and Ropivacaine due to competitive inhibition of the same metabolic pathway. Corneal disease [9A76-9A78] [13]
Mycophenolic acid DMU65NK Minor Increased plasma concentration of PMID28870136-Compound-48 and Mycophenolic acid due to competitive binding of plasma proteins. Crohn disease [DD70] [25]
Osilodrostat DMIJC9X Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [26]
Aminoglutethimide DMWFHMZ Moderate Increased metabolism of PMID28870136-Compound-48 caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [27]
Nefazodone DM4ZS8M Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [28]
Primidone DM0WX6I Moderate Increased metabolism of PMID28870136-Compound-48 caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Mephenytoin DM5UGDK Moderate Increased metabolism of PMID28870136-Compound-48 caused by Mephenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Stiripentol DMMSDOY Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [30]
Fosphenytoin DMOX3LB Moderate Increased metabolism of PMID28870136-Compound-48 caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Ethotoin DMXWOCP Moderate Increased metabolism of PMID28870136-Compound-48 caused by Ethotoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Phenobarbital DMXZOCG Moderate Increased metabolism of PMID28870136-Compound-48 caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Carbamazepine DMZOLBI Moderate Increased metabolism of PMID28870136-Compound-48 caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Cannabidiol DM0659E Moderate Increased metabolism of PMID28870136-Compound-48 caused by Cannabidiol mediated induction of CYP450 enzyme. Epileptic encephalopathy [8A62] [16]
Ketoconazole DMPZI3Q Minor Altered absorption of PMID28870136-Compound-48 caused by Ketoconazole. Fungal infection [1F29-1F2F] [32]
Nizatidine DMGFV3Z Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Nizatidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [33]
Cimetidine DMH61ZB Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [33]
Isoniazid DM5JVS3 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [34]
Rifampin DMA8J1G Moderate Increased metabolism of PMID28870136-Compound-48 caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [34]
Ritonavir DMU764S Moderate Increased metabolism of PMID28870136-Compound-48 caused by Ritonavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Teriflunomide DMQ2FKJ Moderate Increased metabolism of PMID28870136-Compound-48 caused by Teriflunomide mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [16]
Verapamil DMA7PEW Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [36]
Diltiazem DMAI7ZV Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [36]
Felodipine DMOSW35 Minor Altered absorption of PMID28870136-Compound-48 caused by Felodipine. Hypertension [BA00-BA04] [37]
Givosiran DM5PFIJ Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [38]
Febuxostat DMDEXQ0 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Febuxostat mediated inhibition of non-CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [39]
Amobarbital DM0GQ8N Moderate Increased metabolism of PMID28870136-Compound-48 caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [15]
Pentobarbital DMFNH7L Moderate Increased metabolism of PMID28870136-Compound-48 caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [15]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of PMID28870136-Compound-48 and Polyethylene glycol. Irritable bowel syndrome [DD91] [40]
Methotrexate DM2TEOL Moderate Decreased renal excretion of PMID28870136-Compound-48 caused by Methotrexate. Leukaemia [2A60-2B33] [41]
Ceritinib DMB920Z Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [16]
Osimertinib DMRJLAT Moderate Increased metabolism of PMID28870136-Compound-48 caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [42]
Capmatinib DMYCXKL Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [43]
Blinatumomab DMGECIJ Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [44]
Vemurafenib DM62UG5 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [45]
Ethinyl estradiol DMODJ40 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Ethinyl estradiol. Menopausal disorder [GA30] [23]
Exjade DMHPRWG Major Decreased metabolism of PMID28870136-Compound-48 caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [46]
Riluzole DMECBWN Minor Decreased metabolism of PMID28870136-Compound-48 caused by Riluzole mediated inhibition of CYP450 enzyme. Motor neuron disease [8B60] [47]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of PMID28870136-Compound-48 and Bupropion. Nicotine use disorder [6C4A] [48]
Rofecoxib DM3P5DA Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Rofecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [49]
Olaparib DM8QB1D Moderate Increased metabolism of PMID28870136-Compound-48 caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [16]
Rucaparib DM9PVX8 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [50]
Thiabendazole DM7YCK3 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Thiabendazole. Parasitic worm infestation [1F90] [51]
Abametapir DM2RX0I Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [52]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of PMID28870136-Compound-48 and Lindane. Pediculosis [1G00] [53]
Ranitidine DM0GUSX Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Ranitidine mediated inhibition of CYP450 enzyme. Peptic ulcer [DA61] [33]
Famotidine DMRL3AB Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Famotidine mediated inhibition of CYP450 enzyme. Peptic ulcer [DA61] [33]
Lefamulin DME6G97 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [54]
Flutamide DMK0O7U Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Flutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [16]
Ustekinumab DMHTYK3 Moderate Altered metabolism of PMID28870136-Compound-48 due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [13]
Ixekizumab DMXW92T Moderate Altered metabolism of PMID28870136-Compound-48 due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [13]
Temsirolimus DMS104F Moderate Increased plasma concentrations of PMID28870136-Compound-48 and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [55]
Tocilizumab DM7J6OR Moderate Altered metabolism of PMID28870136-Compound-48 due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [13]
Canakinumab DM8HLO5 Moderate Altered metabolism of PMID28870136-Compound-48 due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [13]
Rilonacept DMGLUQS Moderate Altered metabolism of PMID28870136-Compound-48 due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [13]
Golimumab DMHZV7X Moderate Altered metabolism of PMID28870136-Compound-48 due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [13]
Sarilumab DMOGNXY Moderate Altered metabolism of PMID28870136-Compound-48 due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [13]
Larotrectinib DM26CQR Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [16]
Norethindrone DMTY169 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Norethindrone. Solid tumour/cancer [2A00-2F9Z] [23]
Disulfiram DMCL2OK Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Disulfiram mediated inhibition of CYP450 enzyme. Substance abuse [6C40] [56]
Fostamatinib DM6AUHV Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [57]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of PMID28870136-Compound-48 and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [55]
Mycophenolate mofetil DMPQAGE Minor Increased plasma concentration of PMID28870136-Compound-48 and Mycophenolate mofetil due to competitive binding of plasma proteins. Transplant rejection [NE84] [25]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of PMID28870136-Compound-48 and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [55]
Cinoxacin DM4EWNS Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Cinoxacin mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [19]
Nalidixic acid DMRM0JV Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Nalidixic acid mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [19]
Enoxacin DMYTE6L Major Decreased metabolism of PMID28870136-Compound-48 caused by Enoxacin mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [58]
Disopyramide DM5SYZP Moderate Increased plasma concentrations of PMID28870136-Compound-48 and Disopyramide due to competitive inhibition of the same metabolic pathway. Ventricular tachyarrhythmia [BC71] [59]
Mexiletine DMCTE9R Major Decreased metabolism of PMID28870136-Compound-48 caused by Mexiletine mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [60]
Amiodarone DMUTEX3 Moderate Decreased metabolism of PMID28870136-Compound-48 caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [61]
⏷ Show the Full List of 94 DDI Information of This Drug

References

1 BDDCS applied to over 900 drugs
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4 Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
5 Clinical pipeline report, company report or official report of Agenus.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Discovery of AB680: A Potent and Selective Inhibitor of CD73. J Med Chem. 2020 Oct 22;63(20):11448-11468.
8 ClinicalTrials.gov (NCT04322006) A Phase I/II Study of TJ004309 for Advanced Solid Tumor. U.S. National Institutes of Health.
9 Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.
10 CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol. 2020 Apr 15;11:508.
11 Clinical pipeline report, company report or official report of Surface oncology.
12 Product Information. Myalept (metreleptin). Bristol-Myers Squibb, Princeton, NJ.
13 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
14 Product Information. Cognex (tacrine). Parke-Davis, Morris Plains, NJ.
15 Bukowskyj M, Nakatsu K, Munt PW "Theophylline reassessed." Ann Intern Med 101 (1984): 63-73. [PMID: 6145380]
16 Cerner Multum, Inc. "Australian Product Information.".
17 Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, Awni WM "Effect of zileuton on theophylline pharmacokinetics." Clin Pharmacokinet 29(suppl 2 (1995): 77-83. [PMID: 8620674]
18 Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
19 Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986): 187-93. [PMID: 3542945]
20 Bachmann KA, Schwartz JI, Jauregui L "Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements." Br J Clin Pharmacol 26 (1988): 191-4. [PMID: 3207556]
21 Amsden GW "Erythromycin, clarithromycin, and azithromycin: are the differences real?" Clin Ther 18 (1996): 56-72. [PMID: 8851453]
22 Gotz VP, Ryerson GG "Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease." Drug Intell Clin Pharm 20 (1986): 694-6. [PMID: 3757782]
23 Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R "Effects of tobacco smoking and oral contraceptive use on theophylline disposition." Br J Clin Pharmacol 16 (1983): 271-80. [PMID: 6626419]
24 Efthymiopoulos C, Bramer SL, Maroli A, Blum B "Theophylline and warfarin interaction studies with grepafloxacin." Clin Pharmacokinet 33(Suppl 1) (1997): 39-46. [PMID: 9433655]
25 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
26 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
27 Lonning PE, Kvinnsland S, Bakke OM "Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer." Clin Pharmacol Ther 36 (1984): 796-802. [PMID: 6499359]
28 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
29 Crowley JJ, Cusack BJ, Jue SG, et al "Cigarette smoking and theophylline metabolism: effects of phenytoin." Clin Pharmacol Ther 42 (1987): 334-40. [PMID: 3621789]
30 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
31 Mitchell EA "Interaction between carbamazinepine and theophylline." N Z Med J 1 (1986): 69-70. [PMID: 3080715]
32 Brown MW, Maldonado AL, Meredith CG, Speeg KV "Effect of ketoconazole on hepatic oxidative drug metabolism." Clin Pharmacol Ther 37 (1985): 290-7. [PMID: 3971653]
33 Anderson JR, Poklis A, Slavin RG "A fatal case of theophylline intoxication." Arch Intern Med 143 (1983): 559-60. [PMID: 6830388]
34 Dal Negro R, Turco P, Trevisan F, De Conti F "Rifampicin-isoniazid and delayed elimination of theophylline: a case report." Int J Clin Pharmacol Res 8 (1988): 275-7. [PMID: 3182118]
35 Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents [published correction appears in Clin Pharmacokinet 1998 Dec;35(6):473]. Clin Pharmacokinet. 1998;35(4):275-291. [PMID: 9812178]
36 Abernethy DR, Egan JM, Dickinson TH, Carrum G "Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans." J Pharmacol Exp Ther 244 (1988): 994-9. [PMID: 3252045]
37 Bratel T, Billing B, Dahlqvist R "Felodipine reduces the absorption of theophylline in man." Eur J Clin Pharmacol 36 (1989): 481-5. [PMID: 2753066]
38 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
39 Product Information. Uloric (febuxostat). Takeda Pharmaceuticals America, Lincolnshire, IL.
40 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
41 Glynn-Barnhart A, Szefler S, Cott G "Effect of methotrexate on prednisolone and theophylline pharmacokinetics." Clin Pharmacol Ther 47 (1990): 130. [PMID: 1880318]
42 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
43 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
44 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
45 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
46 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
47 Product Information. Rilutek (riluzole). Rhone-Poulenc Rorer, Collegeville, PA.
48 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
49 Product Information. Vioxx (rofecoxib). Merck & Co, Inc, West Point, PA.
50 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
51 Lew G, Murray WE, Lane JR, Haeger E "Theophylline-thiabendazole drug interaction." Clin Pharm 8 (1989): 225-7. [PMID: 2706897]
52 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
53 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
54 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
55 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
56 Loi CM, Day JD, Jue SG, et al "Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics." Clin Pharmacol Ther 45 (1989): 476-86. [PMID: 2721103]
57 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
58 Beckmann J, Elsaber W, Gundert-Remy U, Hertrampf R "Enoxacin: a potent inhibitor of theophylline metabolism." Eur J Clin Pharmacol 33 (1987): 227-30. [PMID: 3480222]
59 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
60 Hurwitz A, Vacek JL, Botteron GW, et al "Mexiletine effects on theophylline disposition." Clin Pharmacol Ther 50 (1991): 299-307. [PMID: 1914365]
61 Soto J, Sacristan JA, Arellano F, Hazas J "Possible theophylline-amiodarone interaction." DICP 24 (1990): 1115. [PMID: 2275239]